Literature DB >> 7577722

Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP.

M O Joly-Pharaboz1, M C Soave, B Nicolas, F Mebarki, M Renaud, O Foury, Y Morel, J G Andre.   

Abstract

UNLABELLED: The paradoxical androgen response of R2, a subline of the human prostate cancer cell line LNCaP, is described here. Two androgens (DHT and R1881) decreased, in a dose-dependent manner, R2 cell proliferation and [3H]thymidine incorporation. These ligand and cell specific effects were accompanied by an increase in the metabolism of the vital dye MTT and in cell protein content. Both androgens increased the doubling time and the percentage of G0-G1 cells. No evidence of androgen-induced apoptosis was found. Cloning allowed the selection of two cell populations on the basis of the response to 10 nM of R1881. Long term culture of uncloned R2 cells with R1881 modified reversibly the pattern of androgen response. R2 was compared to the androgen-stimulated LNCaP-FGC subline to investigate the causes of their different androgen responsiveness. The androgen receptor (number, affinity for hormones and antihormones, sedimentation constant and molecular weight) and androgen receptor genes (exon size and exon 8 sequence) were found to be identical in the two sublines. EGF stimulated LNCaP-FGC but not R2. Both cells were slightly stimulated by basic FGF but were insensitive to IGF-I and TGF beta 1. IN
CONCLUSION: (1) androgens inhibit the proliferation of R2 cells possibly by introducing a G0-G1 block; (2) this inhibition is incomplete because, at least in part, the R2 cell population is heterogeneous; (3) chronic androgen treatment induces reversible cell adaptation; and (4) there is no evidence that the loss of the classical stimulatory effect of androgen on cell proliferation and the gain of inhibitory effect are due to androgen receptor alteration or to a specific action of one of the four growth factors tested.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7577722     DOI: 10.1016/0960-0760(95)00155-s

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  6 in total

1.  Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.

Authors:  Michael J Morris; Daisy Huang; William K Kelly; Susan F Slovin; Ryan D Stephenson; Caitlin Eicher; Anthony Delacruz; Tracy Curley; Lawrence H Schwartz; Howard I Scher
Journal:  Eur Urol       Date:  2009-04-03       Impact factor: 20.096

2.  Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.

Authors:  Y Umekita; R A Hiipakka; J M Kokontis; S Liao
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

3.  Ligand activation of the androgen receptor downregulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells.

Authors:  Joanna Nightingale; Khurram S Chaudhary; Paul D Abel; Andrew P Stubbs; Hanna M Romanska; Stephen E Mitchell; Gordon W H Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2003 Jul-Aug       Impact factor: 5.715

Review 4.  The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer.

Authors:  Sheng-Qiang Yu; Kuo-Pao Lai; Shu-Jie Xia; Hong-Chiang Chang; Chawnshang Chang; Shuyuan Yeh
Journal:  Asian J Androl       Date:  2008-12-22       Impact factor: 3.285

Review 5.  Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.

Authors:  Chih-Pin Chuu; John M Kokontis; Richard A Hiipakka; Junichi Fukuchi; Hui-Ping Lin; Ching-Yu Lin; Chiech Huo; Liang-Cheng Su
Journal:  J Biomed Sci       Date:  2011-08-23       Impact factor: 8.410

Review 6.  Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.

Authors:  Osama S Mohammad; Michael D Nyquist; Michael T Schweizer; Stephen P Balk; Eva Corey; Stephen Plymate; Peter S Nelson; Elahe A Mostaghel
Journal:  Cancers (Basel)       Date:  2017-12-06       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.